Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
CTC-CEC-ADN
1 other identifier
interventional
360
1 country
3
Brief Summary
Fifteen cohorts will be opened. Each cohort will explore one analysis method and/or tumoral type. Up to 50 patient can be included into each cohort.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2010
Longer than P75 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2010
CompletedFirst Submitted
Initial submission to the registry
August 8, 2014
CompletedFirst Posted
Study publicly available on registry
August 20, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2018
CompletedAugust 8, 2025
August 1, 2025
7.5 years
August 8, 2014
August 7, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
CTC, CEC or ctDNA incidence
number of CTC or CEC in 7.5ml of blood
3 years
Secondary Outcomes (2)
CTC and CEC molecular characterization
3 years
Circulating tumor DNA (ctDNA) detection and quantification
3 years
Interventions
Eligibility Criteria
You may qualify if:
- years old or more
- Performance status from 0 to 4
- Patient treated followed for histologically confirmed solid tumor type of any of these localization : breast, prostate, uterus, ovary, colon, lung, head and neck, melanoma.
- Informed consent form signed.
You may not qualify if:
- Patient with history of other invasive cancer within 5 years.
- Patient treated for any non-invasive cancer
- Patient individually deprived of liberty or placed under the authority of a tutor
- Geographical condition potentially preventing compliance with the study protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Institut Curielead
Study Sites (3)
Institut Curie
Paris, 75005, France
Institut Mutualiste Montsouris
Paris, 75014, France
Institut Curie
Saint-Cloud, 92210, France
Related Publications (2)
Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lievre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W. Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.
PMID: 30054279BACKGROUNDCabel L, Decraene C, Bieche I, Pierga JY, Bennamoun M, Fuks D, Ferraz JM, Lefevre M, Baulande S, Bernard V, Vacher S, Mariani P, Proudhon C, Bidard FC, Louvet C. Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. Cancers (Basel). 2019 Mar 21;11(3):396. doi: 10.3390/cancers11030396.
PMID: 30901876BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jean-Yves Pierga, Prof.
Institut Curie
- STUDY CHAIR
François-Clément Bidard, MD, PhD
Institut Curie
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 8, 2014
First Posted
August 20, 2014
Study Start
December 1, 2010
Primary Completion
June 1, 2018
Study Completion
June 1, 2018
Last Updated
August 8, 2025
Record last verified: 2025-08